|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||29.22|
|Dividend & Yield||0.78 (2.84%)|
|1y Target Est||N/A|
Categories: Yahoo FinanceGet free summary analysis Takeda Pharmaceutical Co., Ltd. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Takeda Pharmaceutical Co., Ltd. – Pfizer Inc., Amgen Inc., GlaxoSmithKline plc Sponsored ADR, Merck & Co., Inc., Seattle Genetics, Inc., Sanofi Sponsored ADR, Dr. Reddy’s Laboratories Ltd. ... Read more (Read more...)
Takeda CEO Christophe Weber said another multibillion-dollar acquisition was unlikely soon, allaying fears Japan’s largest drugmaker was building up too much debt.
Globalization has been key to Takeda Pharmaceutical's strategy to achieving growth, its CEO said.